{"id":"other-ppi-marketed-in-sweden","safety":{"commonSideEffects":[{"rate":"5–15%","effect":"Headache"},{"rate":"5–15%","effect":"Diarrhea"},{"rate":"2–10%","effect":"Abdominal pain"},{"rate":"2–5%","effect":"Nausea"},{"rate":"2–5%","effect":"Constipation"},{"rate":null,"effect":"Hypomagnesemia (with long-term use)"},{"rate":null,"effect":"Vitamin B12 deficiency (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL6068521","moleculeType":"Small molecule","molecularWeight":"815.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PPIs are prodrugs that are activated in the acidic environment of the parietal cell canaliculus and irreversibly inhibit the H+/K+-ATPase pump, the final step of gastric acid secretion. This results in profound and long-lasting suppression of both basal and stimulated gastric acid production, providing relief from acid-related gastrointestinal conditions.","oneSentence":"Proton pump inhibitors (PPIs) block the hydrogen/potassium ATPase pump in gastric parietal cells, reducing gastric acid secretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:12.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Prevention of NSAID-induced ulcers"}]},"trialDetails":[{"nctId":"NCT00272701","phase":"PHASE4","title":"Esomeprazole in PPI Failures - IMPROVE","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Gastroesophageal Reflux Disease","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Other PPI marketed in Sweden","genericName":"Other PPI marketed in Sweden","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Proton pump inhibitors (PPIs) block gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme in parietal cells of the stomach. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}